BISOPROLOL SUMMARY
Bisoprolol fumarate is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent.
Bisoprolol fumarate tablets are indicated in the management of hypertension. They may be used alone or in combination with other antihypertensive agents.
|
NEWS HIGHLIGHTSMedia Articles Related to Bisoprolol
New Consortium Paves The Way For Improved Treatment Of Hypertension And Associated Vascular Complications
Source: Hypertension News From Medical News Today [2009.11.18]
Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
Kids with CKD Often Have Masked Hypertension (CME/CE)
Source: MedPage Today Nephrology [2009.11.13]
Many children with chronic kidney disease may have undetected hypertension, placing them at risk for enlarged hearts and future cardiovascular disease, a cross-sectional study showed.
Key Player Identified In Cascade That Leads To Hypertension-Related Kidney Damage
Source: Hypertension News From Medical News Today [2009.11.06]
A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Medical College of Georgia researchers have found endothelin, a powerful blood vessel constrictor and inflammatory peptide, increases the number of T cells in the kidneys, which helps recruit other immune cells, causing inflammation and destruction.
A Recipe For Hypertension: High Fructose Corn Syrup
Source: Hypertension News From Medical News Today [2009.10.31]
A diet high in fructose increases the risk of developing high blood pressure (hypertension), according to a paper presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, California. The findings suggest that cutting back on processed foods and beverages that contain high fructose corn syrup (HFCS) may help prevent hypertension.
Hypertension Guidelines Reappraised In Light Of New Research
Source: Hypertension News From Medical News Today [2009.10.30]
A Task Force of the European Society of Hypertension have released the official European guidelines on the management and treatment of hypertension. The guidelines are an update of those published in 2007, and will be published in the November issue of the Journal of Hypertension.
Published Studies Related to Bisoprolol
Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. [2009.07]
CONCLUSION: Initiation of bisoprolol in patients with HF and concomitant moderate or severe COPD resulted in a reduction in FEV(1). However, symptoms and quality of life were not impaired.
Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). [2009.06]
OBJECTIVE: This study evaluated the effectiveness and safety of beta-blockers and statins for the prevention of perioperative cardiovascular events in intermediate-risk patients undergoing noncardiovascular surgery. SUMMARY BACKGROUND DATA: Beta-blockers and statins reduce perioperative cardiac events in high-risk patients undergoing vascular surgery by restoring the myocardial oxygen supply/demand balance and/or stabilizing coronary plaques. However, their effects in intermediate-risk patients remained ill-defined... CONCLUSION: Bisoprolol was associated with a significant reduction of 30-day cardiac death and nonfatal MI, while fluvastatin showed a trend for improved outcome.
Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. [2008.06]
OBJECTIVE: Individual blood pressure responses to antihypertensive therapy are difficult to predict. To improve optimization of antihypertensive therapy, we analyzed correlations of relevant laboratory tests with blood pressure responses to four antihypertensive monotherapies... CONCLUSIONS: In this carefully controlled study, marked individual variations in antihypertensive drug responsiveness were found to correlate to several baseline laboratory parameters. The negative correlation between serum calcium levels and amlodipine responses is intriguing and suggests an underlying mechanistic association. Collectively, our data imply that laboratory tests may have some value in prediction of the efficacy of various antihypertensive drug therapies, although great patient-to-patient variation remains an obstacle for exact predictive classification.
Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure. [2007.12]
INTRODUCTION: Several beta blocking drugs (BB) reduce mortality in systolic heart failure (LVSD). We have compared the initial response to introduction of carvedilol and bisoprolol during the standard dose titration protocols for each drug... CONCLUSIONS: In this study we found similar degrees and rate of onset of HR, HRV and BP response to both carvedilol and bisoprolol in treated LVSD patients. Carvedilol appears to show superior HRV rises compared to bisoprolol during initial titration. Any significant increases in HRV attributable to carvedilol compared to bisoprolol may emerge over a longer treatment interval in LVSD.
Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? [2007.08]
CONCLUSION: Carvedilol and bisoprolol have different effects on DLCO and response to salbutamol. DLCO differences, being DM related, are due to changes in active membrane transport which is under alveolar beta2-receptor control. Peak VO2 was slightly higher with bisoprolol particularly in CHF patients with reduced DLCO.
Clinical Trials Related to Bisoprolol
Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity [Completed]
Chagas disease (CD) is the major cause of disability secondary to tropical diseases in young
adults from Latin America. In this region 20 million people are currently infected by T.
cruzi, the etiologic agent for CD. In Colombia, 18 percent of the population live in CD
endemic areas, 900,000 people are infected and over three million are at high risk of being
infected. Heart failure due to Chagas cardiomyopathy (CCM) is the main clinical form of CD in
Colombia. However, the incidence of CCM among T. cruzi infected people is unknown and the
mechanisms that lead from infection to CCM are uncertain. Besides the poor prognosis of CHF
due to Chagas disease, it is important to estimate the risk of complications and death in
patient infected with T. cruzi Unfortunately, few clinical studies have addressed this issue.
Most T. cruzi infected patients have mild or no clinical disease, however, the percentage of
infected people that will develop detectable cardiac abnormalities is approximately 30 to 40
percent, but only 20 percent of them will develop symptomatic cardiac involvement. Like CHF
from other causes, CHF due to CD responds to digital, diuretics and vasodilators therapy.
Also, some studies have shown that angiotensin-converting enzyme (ACE) inhibitors improve
survival in patients with moderate to severe CHF due to CD. Increased sympathetic drive
results in an increased risk of cardiac arrhythmia and sudden death. Beta-adrenoreceptor
antagonism seems to protect against the deleterious effects of chronic sympathetic
stimulation. The effects of the selective beta-adrenergic receptor blocker Bisoprolol on
cardiovascular mortality, hospital readmission due to progressive heart failure and
functional status in patients with CHF secondary to CCM has not been explored to-date. To
evaluate the benefit of Bisoprolol in CHF due to CCM, a cohort of T. cruzi seropositive
patients will be selected from several institutions in Colombia. Patients will be classified
according to a modified version of the Panamerican Health Organization recommendations for
patients with CCM. Overall one year mortality in patients with CHF due to Chagas disease has
been reported as 34 percent. However, one year mortality is only 3 percent in patients in
NYHA functional class II, 27 percent in those in NYHA functional class III, and 62 percent
among those in functional class IV (22). The sample size has been calculated assuming an
event rate of 40 percent in two years in the placebo group, and using a 95 percent confidence
level and power of 80 percent, we will need to recruit 250 patients per treatment arm to
detect a reduction of 30 percent in the risk of the primary outcome. The event rate we have
used to estimate sample size is similar to the expected two-year mortality in patients with
CHF due to Chagas disease in NYHA functional class II. Therefore, the estimated sample size
should be enough to measure significant changes in the composite primary outcome (death, HF
hospitalizations, SMVT, SCD). The recruitment process will follow guidelines set out by the
FCV Ethics Committee. Most participants will be recruited from the Chagas disease and the
Heart Failure clinics located in Bucaramanga, Bogotá and Cucuta. During the pretreatment
period an initial evaluation visit will be scheduled in which participants will sign consent
forms, baseline measurements and tests will be conducted at the FCV including blood pressure
measurements obtained with patients in the sitting and standing positions. Laboratory test
such as twelve-lead ECG will be recorded in each patient. Left ventricular ejection fraction
at rest will be determined by 2D echocardiography, using a modified Simpsons rule to
calculate LV volumes. Quality of life questionnaire will be performed two weeks apart during
baseline examination using the Minnesota living with heart failure questionnaire. Minimum of
two 6-minutes corridor walk test once a week over a two-week period will be performed to
measure the functional class. During the treatment period patients will be randomly assigned
to receive double-blind Bisoprolol or placebo, initially taking a total daily dose of 2. 5
mgrs qd. The dose will be increased every two weeks to 5 up to 7. 5 and 10 mgrs qd (maximum
maintenance dose). Follow-up assessment will include clinical check-up, and blood collection
for future measurements of inflammatory reactants and markers. Quality of life measurements
will be obtained at six months. Following the descriptive analysis we will compare the
patient survival and hospitalization rates using Kaplan-Meier estimates and survival graphs.
Cox regression will be used for the multivariate analysis of time to death and time to
hospitalization. This analysis will allow us to explore the pattern of changes in patients
with chronic heart failure due to Chagas disease such as the effect of beta-blockers in this
special type of cardiomyopathy.
Treating Clozapine-Induced Sinustachycardia With Bisoprolol [Recruiting]
Clozapine-induced sinustachycardia occurs in 25% of patients treated with clozapine and
sustained sinustachycardia might be a risk factor for dilated cardiomyopathy. This
double-blinded cross over placebo controlled study investigate whether 10 mg bisoprolol are
efficient in treating clozapine-induced sinustachycardia measured as heart rate, heart rate
variability, QTc and T-wave morphology.
Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure [Recruiting]
We test the hypothesis that different beta-blockers had a different influence on
chemoreceptor response and lung diffusion capacity.
Both could influence exercise capacity in normoxic as well as hypoxic conditions.
Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia [Completed]
There is a lack of data on the prognostic importance of silent ischemia in totally
asymptomatic subjects without history of coronary artery disease (CAD), and, particularly, on
a possible benefit of medical therapy in such patients. SWISSI 1 therefore recruits totally
asymptomatic subjects older than 40 years of age without any history of CAD but one
cardiovascular risk factor with documented silent ischemia. Participants are randomized to
open antianginal drug therapy and risk factor control versus only risk factor management and
followed up for ≥ 10 years.
Evaluation of Heart Failure Treatment Guided by NTproBNP vs Clinical Symptoms and Signs Alone [Recruiting]
The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms
and signs is more effective than treatment guided by clinical symptoms and signs alone in
patients with HF and left ventricular systolic dysfunction
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Bisoprolol has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Bisoprolol review by 61 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | palpitations |
| Dosage & duration: | | 10mg taken daily for the period of 10 + years |
| Other conditions: | | BP, cholesterol |
| Other drugs taken: | | zocor | | |
Reported Results |
| Benefits: | | Immediately controled palpitations associated with mild to moderate mitral valve regurtitation |
| Side effects: | | none |
| Comments: | | one time daily |
|
|
|
Page last updated: 2009-11-18
|
